A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)
Summary
- Eligibility
- for people ages 18-100 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Amgen
- Links
- AmgenTrials clinical trials website
- ID
- NCT05651711
- Phase
- Phase 3 Atopic Dermatitis (Eczema) Research Study
- Study Type
- Interventional
- Participants
- Expecting 680 study participants
- Last Updated